Last reviewed · How we verify
xylometazoline HCL 0.05%
At a glance
| Generic name | xylometazoline HCL 0.05% |
|---|---|
| Also known as | xylometazoline HCL = Otrivin nasal drops |
| Sponsor | Schneider Children's Medical Center, Israel |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media (NA)
- Nasal Prep for Nasendoscopy in Children (PHASE4)
- The Influence of Inhaled Adrenalin Versus Decongestant as a Local Nasal Treatment in Bronchiolitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- xylometazoline HCL 0.05% CI brief — competitive landscape report
- xylometazoline HCL 0.05% updates RSS · CI watch RSS
- Schneider Children's Medical Center, Israel portfolio CI